Molecure

Name: Molecure
Address: Ulica Żwirki i Wigury 101, Warsaw, 02-089, PL
Telephone: +48225526724

Molecure S.A. to innowacyjna firma biotechnologiczna. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Molecure is a clinical stage biopharmaceutical company that uses its world leading medicinal chemistry capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and underexplored protein targets to treat multiple incurable diseases. Molecure has generated a diverse pipeline of nine distinct programs with the support of leading academic life scien

ce institutions globally, including the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science. Molecure’s most advanced in-house compound is OATD-02, an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer that is expected to advance to Phase 1 in the second half of 2022. Molecure has an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of Molecure’s OATD-01. OATD-01 (GLPG4716) is a Phase 2-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases with a fibrotic component. Molecure’s headquarters and laboratories are located in Warsaw, Poland with an additional laboratories in Łódź.

12/08/2026

📣 We're pleased to share a recent interview with representatives of , published by Strefa Inwestorów - Praktycznie o inwestowaniu🎙️

In the conversation, Marcin Szumowski (CEO), Zbigniew Zasłona (CSO) and Dariusz Stencel (CMO) discuss the latest progress of our lead clinical program, , including the positive Independent Data Monitoring Committee (IDMC) recommendation to continue the Phase II study without modifications following its review of the first 30 patients.

The interview also explores the broader therapeutic potential of OATD-01, the current partnering landscape, and the key milestones expected as the program continues to advance 🔬

➡️ Read the full interview here: https://strefainwestorow.pl/biotechnologia/molecure-oatd-01

24/07/2026

We are pleased to announce that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of our global Phase II study of in patients with active pulmonary sarcoidosis, with no changes to the current study protocol ✅

Following a review of the complete safety and efficacy dataset from 30 patients, the IDMC concluded that the results support continued development of the study. We are now randomizing an additional 20 patients ahead of the second and final interim analysis, which will include data from a total of 50 patients 🔬

This recommendation marks an important milestone for and another step forward in advancing towards Phase III and our ultimate goal of improving patient lives. 📈

➡️ Read more: https://molecure.com/molecure-receives-positive-idmc-recommendation-to-continue-the-kite-clinical-trial-without-changes-to-the-study-protocol-oatd-01-development-program/

22/07/2026

Last week, our team joined the Conference in Porto 🇵🇹

It was a great opportunity to connect with the international sarcoidosis community, exchange insights, and raise awareness of our Study evaluating , our investigational CHIT1 inhibitor for the treatment of pulmonary sarcoidosis 🔬

We were proud to have Dariusz Stencel (Chief Medical Officer), Theodoros Charitos (Medical Director) and Geolyce Mpofu (Director, Patient Recruitment and Site Engagement) representing at the conference and engaging with researchers, clinicians, and experts working to advance treatment options for people living with sarcoidosis 🤝

22/06/2026

Starting today, the team will be attending the BIO International Convention 2026, one of the world's leading biotechnology partnering events! 🔬

Our team will be represented by Marcin Szumowski - CEO, Zbigniew Zasłona - CSO and Maurycy Zieliński - Business Development Director 💼

We're excited about the inspiring conversations, new connections, and opportunities to share Molecure's vision and progress in developing breakthrough therapies. See you at ! 🚀

29/05/2026

We are pleased to announce another important milestone in the clinical development of 📣

has completed the dose-limiting toxicity (DLT) observation period in all patients treated with OATD-02 at the 40 mg QD dose level. Following review of the data collected so far, and with approval from the Safety Review Committee (SRC), the study has progressed to the 80 mg QD dose level.

Importantly, the data confirmed therapeutic target engagement - a key step toward identifying the pharmacologically active dose of our investigational arginase inhibitor. continues to advance in Phase 1 clinical development as a potential novel therapy in oncology! 🌍

21/05/2026

We are pleased to announce that has been granted a US patent (US12612420 (B2)) for the latest series of arginase inhibitors! 📣

These inhibitors are backup compounds for , a frontrunner that is performing well in Phase 1 clinical trials (NCT05759923, https://clinicaltrials.gov/study/NCT05759923?term=oatd-02&viewType=Card&rank=1). This achievement underscores Molecure's global leadership in the field of arginase inhibitors 🌍

➡️Link to the patent: https://worldwide.espacenet.com/patent/search/family/079287969/publication/US12612420B2?q=pn%3DUS12612420B2

20/05/2026

We are excited to share that our team members, Theodoros Charitos (Medical Director) and Katarzyna Drzewicka (Head of Early Discovery), are attending the International Conference in Orlando, FL (US) 🇺🇸

Our team, along with renowned co-authoring pulmonology and nuclear medicine clinicians, is showcasing the Phase 2 Study in pulmonary sarcoidosis and highlighting ’s ongoing work on . This abstract, in form of a poster, presents approaches to evaluating treatment response using advanced PET imaging methodologies. It is presented in the scientific session dedicated to biomarkers, imaging, and physiology in Interstitial Lung Diseases (ILDs) taking place today, May 20th, 2026. Its title is “Novel Semi-quantitative Fluorodeoxyglucose Positron Emission Tomography Response Criteria as Primary Endpoint in Pulmonary Sarcoidosis: Methodological Design and Implementation in the KITE Phase 2 Study” 🔬

Molecure team is proud to be part of the global scientific community efforts around innovative therapies for pulmonary diseases including ILDs/pulmonary sarcoidosis 🌍

13/05/2026

🎙️ Our CEO, Marcin Szumowski, joined inwestorzy.tv, where he spoke about ’s key priorities, including progress in the study for , ongoing partnering discussions, and the potential of projects developed in inflammatory and oncology diseases 🔬

The interview also highlights the company’s development outlook and upcoming milestones important for investors following the biotech sector 📈

➡️ Watch the full interview here: https://www.youtube.com/watch?v=7j4Bjn0zH3k&feature=youtu.be

07/05/2026

, in collaboration with and , explores targeting ubiquitin-specific protease 7 ( ) 📖

is a deubiquitinating enzyme frequently overexpressed in cancer and linked to stabilization of oncogenic proteins and immunosuppressive factors. Structure-guided discovery and SAR-driven optimization efforts yielded selective USP7 inhibitors to explore this therapeutic target, with OAT-4828 emerging as a potent lead compound. The screening cascade, which led to the discovery of OAT-4828 incorporated cellular system, including primary T cells, where the compound increased T-cell killing capacity without causing toxicity – highlighting a scientifically new role of USP7 in immune cell activation. The pharmacokinetic profile in mice and preliminary safety assessments of OAT-4828 enabled in vivo studies. OAT-4828 was well-tolerated in mice, demonstrating significant antileukemic activity in a syngeneic model of B-cell derived non-Hodgkin lymphoma without systemic toxicity.

One of the key substrates regulated by USP7 is . With several MDM2 inhibitors currently in clinical development, the p53-MDM2 axis is firmly validated as a critical therapeutic target. Our latest research highlights how USP7 inhibition may offer a powerful, upstream approach to modulate this proven pathway.

Read more ➡️ https://pubs.acs.org/doi/10.1021/acs.jmedchem.6c00407

07/05/2026

We are proud to share that our R&D Operations Director, Barbara Dymek, has been nominated to the TOP 100 Women in Biotech in Poland ranking by Perspektywy Women in Tech 👩‍⚕️

This prestigious recognition highlights outstanding female leaders shaping the future of biotechnology and inspiring the next generation in a field where women’s representation remains especially important.

The winners will be selected by an esteemed jury, with the official announcement and the Excellence in Biotech Awards ceremony taking place on June 10-11 during the Perspektywy Women in Tech Summit 2026 in Warsaw 🥇

More information: https://womenintechsummit.pl/top-100-women

Congratulations on this well-deserved nomination! 🎉

Adres

Ulica Żwirki I Wigury 101
Warsaw
02-089

Telefon

+48225526724

Strona Internetowa

https://molecure.com/

Ostrzeżenia

Bądź na bieżąco i daj nam wysłać e-mail, gdy Molecure umieści wiadomości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu i możesz zrezygnować z subskrypcji w dowolnym momencie.

Chcesz aby twoja firma była na górze listy Firma Inżynieryjna w Warsaw?

Udostępnij

Kategoria

Firma z branży biotechnologii